| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Marc W Manseau, Donald C Gof. Cannabinoids and Schizophrenia: Risks and Therapeutic Potential. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. vol 12. issue 4. 2016-07-22. PMID:26311150. |
the endocannabinoid system has been implicated in psychosis both related and unrelated to cannabis exposure, and studying this system holds potential to increase understanding of the pathophysiology of schizophrenia. |
2016-07-22 |
2023-08-13 |
human |
| Michael Loureiro, Justine Renard, Jordan Zunder, Steven R Laviolett. Hippocampal cannabinoid transmission modulates dopamine neuron activity: impact on rewarding memory formation and social interaction. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 40. issue 6. 2016-03-29. PMID:25510937. |
disturbances in cannabinoid type 1 receptor (cb1r) signaling have been linked to emotional and cognitive deficits characterizing neuropsychiatric disorders, including schizophrenia. |
2016-03-29 |
2023-08-13 |
rat |
| Paula Suárez-Pinilla, Roberto Roiz-Santiañez, Víctor Ortiz-García de la Foz, Paul C Guest, Rosa Ayesa-Arriola, Aldo Córdova-Palomera, Diana Tordesillas-Gutierrez, Benedicto Crespo-Facorr. Brain structural and clinical changes after first episode psychosis: Focus on cannabinoid receptor 1 polymorphisms. Psychiatry research. vol 233. issue 2. 2016-03-29. PMID:26071625. |
these findings suggest that the cannabinoid pathway is associated with schizophrenia evolution over time. |
2016-03-29 |
2023-08-13 |
Not clear |
| J F C Pedrazzi, A C Issy, F V Gomes, F S Guimarães, E A Del-Be. Cannabidiol effects in the prepulse inhibition disruption induced by amphetamine. Psychopharmacology. vol 232. issue 16. 2016-02-23. PMID:25943166. |
clinical and neurobiological findings suggest that the endocannabinoid system and cannabinoids may be implicated in the pathophysiology and treatment of schizophrenia. |
2016-02-23 |
2023-08-13 |
human |
| Tabitha A Iseger, Matthijs G Bosson. A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophrenia research. vol 162. issue 1-3. 2016-01-04. PMID:25667194. |
a highly promising new pharmacological target in the context of schizophrenia is the endocannabinoid system. |
2016-01-04 |
2023-08-13 |
human |
| Tabitha A Iseger, Matthijs G Bosson. A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophrenia research. vol 162. issue 1-3. 2016-01-04. PMID:25667194. |
however, the non-psychotropic, plant-derived cannabinoid agent cannabidiol (cbd) may have antipsychotic properties, and thus may be a promising new agent in the treatment of schizophrenia. |
2016-01-04 |
2023-08-13 |
human |
| Tiziana Rubino, Erica Zamberletti, Daniela Parolar. Endocannabinoids and Mental Disorders. Handbook of experimental pharmacology. vol 231. 2015-12-16. PMID:26408164. |
in this review we will briefly summarize the most common alterations in the endocannabinoid system, in terms of cannabinoid receptors and endocannabinoid levels, present in mood disorders (anxiety, posttraumatic stress disorder, depression, bipolar disorder, and suicidality) as well as psychosis (schizophrenia) and autism. |
2015-12-16 |
2023-08-13 |
human |
| b' Alexandra Gallo, Claude Bouchard, Emmanuel Fortier, Charles Ducrot, Pierre-Paul Rompr\\xc3\\xa. Cannabinoids reward sensitivity in a neurodevelopmental animal model of schizophrenia: a brain stimulation reward study. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 24. issue 9. 2015-11-02. PMID:25092427.' |
cannabinoids reward sensitivity in a neurodevelopmental animal model of schizophrenia: a brain stimulation reward study. |
2015-11-02 |
2023-08-13 |
rat |
| b' Alexandra Gallo, Claude Bouchard, Emmanuel Fortier, Charles Ducrot, Pierre-Paul Rompr\\xc3\\xa. Cannabinoids reward sensitivity in a neurodevelopmental animal model of schizophrenia: a brain stimulation reward study. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 24. issue 9. 2015-11-02. PMID:25092427.' |
to study this question, we investigated the motivational effects of cannabinoid agonists using the brain stimulation reward paradigm and a neurodevelopmental model of schizophrenia: neonatal ventral hippocampus lesions (nvhl). |
2015-11-02 |
2023-08-13 |
rat |
| Felipe V Gomes, Francisco S Guimarães, Anthony A Grac. Effects of pubertal cannabinoid administration on attentional set-shifting and dopaminergic hyper-responsivity in a developmental disruption model of schizophrenia. The international journal of neuropsychopharmacology. vol 18. issue 2. 2015-10-06. PMID:25522381. |
effects of pubertal cannabinoid administration on attentional set-shifting and dopaminergic hyper-responsivity in a developmental disruption model of schizophrenia. |
2015-10-06 |
2023-08-13 |
Not clear |
| Felipe V Gomes, Francisco S Guimarães, Anthony A Grac. Effects of pubertal cannabinoid administration on attentional set-shifting and dopaminergic hyper-responsivity in a developmental disruption model of schizophrenia. The international journal of neuropsychopharmacology. vol 18. issue 2. 2015-10-06. PMID:25522381. |
adolescent exposure to cannabinoids in vulnerable individuals is proposed to be a risk factor for psychiatric conditions later in life, particularly schizophrenia. |
2015-10-06 |
2023-08-13 |
Not clear |
| David D Aguilar, Li Chen, Daniel J Lodg. Increasing endocannabinoid levels in the ventral pallidum restore aberrant dopamine neuron activity in the subchronic PCP rodent model of schizophrenia. The international journal of neuropsychopharmacology. vol 18. issue 1. 2015-09-30. PMID:25539511. |
increasing endocannabinoid levels in the ventral pallidum restore aberrant dopamine neuron activity in the subchronic pcp rodent model of schizophrenia. |
2015-09-30 |
2023-08-13 |
Not clear |
| David D Aguilar, Li Chen, Daniel J Lodg. Increasing endocannabinoid levels in the ventral pallidum restore aberrant dopamine neuron activity in the subchronic PCP rodent model of schizophrenia. The international journal of neuropsychopharmacology. vol 18. issue 1. 2015-09-30. PMID:25539511. |
while the exogenous administration of cannabinoids such as tetrahydrocannabinol is reported to exacerbate psychosis in schizophrenia patients, augmenting the levels of endogenous cannabinoids has gained attention as a possible alternative therapy to schizophrenia due to clinical and preclinical observations. |
2015-09-30 |
2023-08-13 |
Not clear |
| David D Aguilar, Li Chen, Daniel J Lodg. Increasing endocannabinoid levels in the ventral pallidum restore aberrant dopamine neuron activity in the subchronic PCP rodent model of schizophrenia. The international journal of neuropsychopharmacology. vol 18. issue 1. 2015-09-30. PMID:25539511. |
thus, patients with schizophrenia demonstrate an inverse relationship between psychotic symptoms and levels of the endocannabinoid anandamide. |
2015-09-30 |
2023-08-13 |
Not clear |
| David D Aguilar, Li Chen, Daniel J Lodg. Increasing endocannabinoid levels in the ventral pallidum restore aberrant dopamine neuron activity in the subchronic PCP rodent model of schizophrenia. The international journal of neuropsychopharmacology. vol 18. issue 1. 2015-09-30. PMID:25539511. |
in addition, increasing endocannabinoid levels (by blockade of enzymatic degradation) has been reported to attenuate social withdrawal in a preclinical model of schizophrenia. |
2015-09-30 |
2023-08-13 |
Not clear |
| Pilar Sánchez-Blázquez, María Rodríguez-Muñoz, Raquel Herrero-Labrador, Javier Burgueño, Daniel Zamanillo, Javier Garzó. The calcium-sensitive Sigma-1 receptor prevents cannabinoids from provoking glutamate NMDA receptor hypofunction: implications in antinociception and psychotic diseases. The international journal of neuropsychopharmacology. vol 17. issue 12. 2015-07-21. PMID:24485144. |
in this framework, the recently reported association of cb1s with nmdars, which mediates the reduction of cannabinoid analgesia promoted by nmdar antagonism, could also support the precipitation of schizophrenia brought about by the abuse of smoked cannabis, mostly among vulnerable individuals. |
2015-07-21 |
2023-08-12 |
mouse |
| Andreja Celofiga, Jure Koprivsek, Janez Klav. Use of synthetic cannabinoids in patients with psychotic disorders: case series. Journal of dual diagnosis. vol 10. issue 3. 2015-07-17. PMID:25392292. |
the psychotropic action of synthetic cannabinoids in patients with schizophrenia is unpredictable, with very diverse clinical presentations. |
2015-07-17 |
2023-08-13 |
Not clear |
| Andreja Celofiga, Jure Koprivsek, Janez Klav. Use of synthetic cannabinoids in patients with psychotic disorders: case series. Journal of dual diagnosis. vol 10. issue 3. 2015-07-17. PMID:25392292. |
we assume that the acute effects of synthetic cannabinoids in patients with schizophrenia would be different from those in persons without psychotic disorders. |
2015-07-17 |
2023-08-13 |
Not clear |
| David W Volk, Stephen M Eggan, Andrew G Horti, Dean F Wong, David A Lewi. Reciprocal alterations in cortical cannabinoid receptor 1 binding relative to protein immunoreactivity and transcript levels in schizophrenia. Schizophrenia research. vol 159. issue 1. 2015-06-22. PMID:25107849. |
the deleterious effects of cannabis use in schizophrenia have been linked, in part, to underlying disturbances in endogenous cannabinoid signaling in the prefrontal cortex. |
2015-06-22 |
2023-08-13 |
human |
| b' Aleksandar Damjanovi\\xc4\\x87, Maja Pantovi\\xc4\\x87, Aleksandra Damjanovi\\xc4\\x87, Bojana Dunji\\xc4\\x87-Kosti\\xc4\\x87, Maja Ivkovi\\xc4\\x87, Sr\\xc4\\x91an Milovanovi\\xc4\\x87, Maja Lackovi\\xc4\\x87, Ivan Dimitrijevi\\xc4\\x8. Cannabis and psychosis revisited. Psychiatria Danubina. vol 27. issue 1. 2015-06-12. PMID:25751443.' |
the association between cannabinoids and psychosis has been known for almost a thousand years, but it is still speculated whether cannabis use may be a contributory cause of psychosis, that is, whether it may precipitate schizophrenia in those at risk. |
2015-06-12 |
2023-08-13 |
Not clear |